It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.
CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several ...
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs ...
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...
CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill ...
In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a ...
CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...
CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results